Dossier assessment
Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Zanubrutinib (chronic lymphocytic leukaemia, relapsed/refractory) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Patients with relapsed/refractory chronic lymphocytic leukaemia
- who have not yet received a Bruton tyrosine kinase (BTK) inhibitor and/or B-cell lymphoma-2 (BCL-2) inhibitor
< 65 years: hint of major added benefit
≥ 65 years: hint of minor added benefit - after prior therapy with at least one BTK inhibitor: added benefit not proven
- after prior therapy with at least one BCL-2 inhibitor: added benefit not proven
- after prior therapy with at least one BTK inhibitor and one BCL-2 inhibitor: added benefit not proven
Press releases
Zanubrutinib in chronic lymphocytic leukaemia: added benefit for certain patients
Project details
- Project no.
- A22-132
- Commission
- Commission awarded on 12.12.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Zanubrutinib (marginal zone lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Zanubrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Zanubrutinib (Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Zanubrutinib (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed